https://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-may-impact-psychedelic-research-20260730-27293The Psychedelic Journalen2026-07-30T15:05:48.574182+00:00EPA's Proposed SNURs May Impact Psychedelic ResearchEPA, SNURs, psychedelic research, chemical substances, TSCA, regulatory compliance, manufacture, import, notification period, regulatory frameworkhttps://mindmedicinelaw.com/briefing/ketamine-s-rapid-antidepressant-effects-clinical-insights-20260729-27676The Psychedelic Journalen2026-07-31T15:09:10.101574+00:00Ketamine's Rapid Antidepressant Effects: Clinical Insightsketamine, treatment-resistant depression, rapid antidepressant effects, NMDA receptor antagonist, long-term safety, optimal dosing, psychiatric treatment, clinical trials, neuropharmacology, glutamatergic signalinghttps://mindmedicinelaw.com/briefing/esketamine-enhances-postoperative-sleep-in-laparoscopic-surgery-20260729-27678The Psychedelic Journalen2026-07-31T15:08:57.825676+00:00Esketamine Enhances Postoperative Sleep in Laparoscopic Surgeryesketamine, postoperative sleep, laparoscopic surgery, opioid reduction, anesthesia, clinical trial, pain management, Huzhou Maternity & Child Health Care Hospital, Pittsburgh Sleep Quality Index, NMDA receptor antagonismhttps://mindmedicinelaw.com/briefing/ketamine-trial-in-suicidal-adolescents-feasibility-in-ed-20260729-27677The Psychedelic Journalen2026-07-31T15:08:19.473347+00:00Ketamine Trial in Suicidal Adolescents: Feasibility in EDketamine, suicidal adolescents, emergency department, clinical trials, psychiatric care, treatment-resistant depression, intravenous administration, adverse effects, rapid-acting antidepressant, mental health researchhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-post-amputation-pain-management-20260729-27414The Psychedelic Journalen2026-07-30T15:05:58.218615+00:00Ketamine's Role in Post-Amputation Pain Managementketamine infusions, postoperative pain management, opioid reduction, limb amputation, public health policy, NMDA receptor, opioid crisis, pain management protocols, clinical trials, ketamine side effectshttps://mindmedicinelaw.com/briefing/eeg-biomarkers-in-psilocybin-treatment-for-depression-20260728-27639The Psychedelic Journalen2026-07-31T15:09:21.954924+00:00EEG Biomarkers in Psilocybin Treatment for Depressionpsilocybin, EEG, MEG, depression treatment, biomarkers, clinical trials, neural oscillations, mental health, predictive biomarkers, neurophysiologyhttps://mindmedicinelaw.com/briefing/key-factors-in-psilocybin-effects-in-mouse-models-identified-20260728-27669The Psychedelic Journalen2026-07-31T15:08:32.040100+00:00Key Factors in Psilocybin Effects in Mouse Models Identifiedpsilocybin, mouse models, behavioral effects, preclinical research, biological factors, experimental variables, psychiatric treatment, 5-HT1B signaling, translational relevance, therapeutic modelshttps://mindmedicinelaw.com/briefing/vet-students-psychedelic-attitudes-impact-therapy-outlook-20260728-27141The Psychedelic Journalen2026-07-29T22:05:52.782672+00:00Vet Students' Psychedelic Attitudes Impact Therapy Outlookveterinary medicine, psychedelic therapies, student attitudes, treatment expectations, educational impact, cognitive frameworkshttps://mindmedicinelaw.com/briefing/hepatic-safety-of-ketamine-and-esketamine-for-trd-patients-20260728-27190The Psychedelic Journalen2026-07-29T22:05:37.332493+00:00Hepatic Safety of Ketamine and Esketamine for TRD Patientsketamine, esketamine, treatment-resistant depression, hepatic safety, liver monitoring, clinical trials, mental health treatment, Mayo Clinic, subanesthetic doseshttps://mindmedicinelaw.com/briefing/neuroimmune-signaling-in-ketamine-and-psychedelic-antidepressant-response-20260728-27189The Psychedelic Journalen2026-07-29T22:05:28.268957+00:00Neuroimmune Signaling in Ketamine and Psychedelic Antidepressant Responseneuroimmune signaling, ketamine, psychedelics, antidepressant response, IL-15, MCP-1, cytokine ratios, treatment-resistant depression, biomarkers, clinical trialshttps://mindmedicinelaw.com/briefing/ssri-dynamics-in-ocd-a-new-model-for-treatment-response-20260727-27145The Psychedelic Journalen2026-07-30T15:06:06.834762+00:00SSRI Dynamics in OCD: A New Model for Treatment ResponseSSRI treatment, obsessive-compulsive disorder, bistable dynamics, clinical trials, individual response, treatment remission, neuroscience, pharmacokinetics, OCD model, treatment strategieshttps://mindmedicinelaw.com/briefing/cardiovascular-risks-of-sympathomimetic-drugs-implications-20260727-27161The Psychedelic Journalen2026-07-29T22:06:12.472828+00:00Cardiovascular Risks of Sympathomimetic Drugs: Implicationssympathomimetic drugs, cardiovascular risks, cocaine, amphetamines, clinical guidelines, toxicological testing, emergency department, catecholamine excess, myocardial toxicity, individualized treatmenthttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-depression-current-research-20260727-27142The Psychedelic Journalen2026-07-29T22:06:04.255782+00:00Ketamine-Assisted Psychotherapy for Depression: Current Researchketamine-assisted psychotherapy, depression treatment, randomized controlled trials, psychotherapy models, mental health research, cognitive behavioral therapy, treatment-resistant depression, clinical guidelines, psychotherapy integration, ketamine riskshttps://mindmedicinelaw.com/briefing/psychedelics-and-chronic-pain-mechanisms-and-barriers-20260727-27143The Psychedelic Journalen2026-07-29T22:05:43.544928+00:00Psychedelics and Chronic Pain: Mechanisms and Barrierspsychedelics, chronic pain, central nervous system, neuroplasticity, clinical trials, expectancy bias, analgesics, neuroscience, pain management, translational barriershttps://mindmedicinelaw.com/briefing/entropic-brain-hypothesis-new-insights-from-diverse-states-20260726-27692The Psychedelic Journalen2026-07-31T15:08:47.170279+00:00Entropic Brain Hypothesis: New Insights from Diverse Statesentropic brain hypothesis, psychedelics, consciousness, brain activity entropy, LSD, DMT, mental health, fMRI, neuroscience, therapeutic applicationshttps://mindmedicinelaw.com/briefing/chlorogenic-acid-s-effects-on-ketamine-induced-schizophrenia-in-rats-20260724-27480The Psychedelic Journalen2026-07-30T22:04:55.748468+00:00Chlorogenic Acid's Effects on Ketamine-Induced Schizophrenia in Ratschlorogenic acid, ketamine, schizophrenia, neuropsychiatric disorders, rats, BDNF expression, sex-dependent effects, dietary interventions, prefrontal cortex, behavioral changeshttps://mindmedicinelaw.com/briefing/social-hierarchy-influences-stress-and-ketamine-effects-in-mice-20260721-27534The Psychedelic Journalen2026-07-30T22:05:07.171327+00:00Social Hierarchy Influences Stress and Ketamine Effects in Micesocial hierarchy, stress response, ketamine treatment, psychiatric disorders, mice study, personalized medicine, transcriptional response, dominant individuals, chronic stress, behavioral alterations